The Ireland Strategic Investment Fund (ISIF) has a minority interest in the Nasdaq-listed biotech company through its partnership with Lightstone Ventures
Immunotherapy company developing next-generation, transformative therapies for the treatment of solid tumors and other immune-mediated diseases in broad.